Literature DB >> 17336474

5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers.

Roberto L Sastre1, Rosa Olmo, César Teijón, Enriqueta Muñíz, José M Teijón, M Dolores Blanco.   

Abstract

Microspheres (MS) of 5-fluorouracil-loaded poly(D,L-lactide) (PLA), poly(D,L-lactide-co-glycolide) 75/25 (PLGA 75/25) and poly(D,L-lactide-co-glycolide) 50/50 (PLGA 50/50) prepared by the spray-drying technique were subcutaneously injected in the back of Wistar rats in order to evaluate the 5-fluorouracil (5-FU) release and the biodegradation characteristics. Determination of plasma 5-FU concentration by HPLC with analysis of data using a non-compartmental model showed drug in plasma between 9 and 14 days after administration of drug-loaded PLGA 50/50 or PLA and PLGA 75/25 microspheres, respectively, with a maximum drug concentration of 2.4+/-0.2microg/mL at 24h (5-FU-loaded PLGA 50/50 MS), 2.5+/-0.1microg/mL at 48h (5-FU-loaded PLGA 75/25 MS), and 2.3+/-0.1microg/mL at 24h (5-FU-loaded PLA MS). Pharmacokinetically, a significant increase of AUC (up to 50 times) and MRT (up to 196 times) of 5-FU with regard to the administration of the drug in solution was observed. Scanning electron microscopy and histological studies indicated that a small fibrous capsule was observed around the microspheres in the site of injection. One month after the injection of PLGA 50/50 MS and 2 months after the injection of PLGA 75/25 and PLA MS, masses of polymers, instead of single microspheres, were observed. Close to them, macrophagic cells were present, and blood vessels were observed in the connective tissue. Total absence of fibrous capsule and injected microspheres was observed after 2 (for PLGA 50/50 MS) or 3 (PLGA 75/25 and PLA MS) months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336474     DOI: 10.1016/j.ijpharm.2007.02.001

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention.

Authors:  Komal Shahani; Suresh Kumar Swaminathan; Diana Freeman; Angela Blum; Linan Ma; Jayanth Panyam
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

2.  Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

Authors:  Hirenkumar K Makadia; Steven J Siegel
Journal:  Polymers (Basel)       Date:  2011-08-26       Impact factor: 4.329

3.  Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.

Authors:  Lekha Nair K; Sankar Jagadeeshan; S Asha Nair; G S Vinod Kumar
Journal:  Int J Nanomedicine       Date:  2011-08-17

4.  Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.

Authors:  Su Li; Anxun Wang; Wenqi Jiang; Zhongzhen Guan
Journal:  BMC Cancer       Date:  2008-04-15       Impact factor: 4.430

Review 5.  Particles from preformed polymers as carriers for drug delivery.

Authors:  K Miladi; D Ibraheem; M Iqbal; S Sfar; H Fessi; A Elaissari
Journal:  EXCLI J       Date:  2014-02-03       Impact factor: 4.068

6.  Application of 5-Fluorouracil-Polycaprolactone Sustained-Release Film in Ahmed Glaucoma Valve Implantation Inhibits Postoperative Bleb Scarring in Rabbit Eyes.

Authors:  Xiu-Zeng Bi; Wei-Hua Pan; Xin-Ping Yu; Zong-Ming Song; Zeng-Jin Ren; Min Sun; Cong-Hui Li; Kai-Hui Nan
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

7.  pH responsive N-succinyl chitosan/Poly (acrylamide-co-acrylic acid) hydrogels and in vitro release of 5-fluorouracil.

Authors:  Shahid Bashir; Yin Yin Teo; Sumaira Naeem; S Ramesh; K Ramesh
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

Review 8.  Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems.

Authors:  José L Arias
Journal:  Molecules       Date:  2008-10-01       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.